Expression and functional activity of CD52 antigen on primary plasma cells and multiple myeloma cell lines.

被引：0
|
作者：
Carlo-Stella, C
Di Nicola, M
Longoni, P
Milanesi, M
Milani, R
Carrabba, M
Gianni, AM
Corradini, P
机构：
[1] Univ Milan, Chair Med Oncol, Milan, Italy
[2] Ist Nazl Tumori, Cristina Gandini Med Oncol Unit, I-20133 Milan, Italy
[3] Ist Nazl Tumori, Hematol & Bone Marrow Transplantat Unit, I-20133 Milan, Italy
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3312
引用
收藏
页码：890A / 890A
页数：1
相关论文
共 50 条
  • [1] Expression of CD52 on plasma cells in plasma cell proliferative disorders
    Kumar, S
    Kimlinger, TK
    Lust, JA
    Donovan, K
    Witzig, TE
    BLOOD, 2003, 102 (03) : 1075 - 1077
  • [2] IL-6 down-regulates CD33 expression in primary myeloma cells as well as myeloma cell lines.
    Shamsasenjan, Karim
    Abroun, Saeid
    Liu, Shngqin
    Amin, Jakia
    Islam, Khademul
    Otsuyama, Ken-ichiro
    Kawano, Michio M.
    BLOOD, 2006, 108 (11) : 340B - 341B
  • [3] Acquirement of resistance to rituximab is associated with upregulation of CD52 antigen: The role of targeting CD52 antigen using alemtuzumab (CAMPATH 1-H) in rituximab-resistant non-Hodgkin's lymphoma (NHL) cell lines.
    Hernandez-Ilizaliturri, FJ
    Bir, AS
    Brombos, D
    Czuczman, MS
    BLOOD, 2003, 102 (11) : 644A - 644A
  • [4] Identifying novel therapeutic targets in myeloma: CD20, CD25 and CD52 expression on malignant plasma cells.
    Singhal, S
    Goolsby, C
    Taylor, R
    Tariman, J
    Karpus, W
    Mehta, J
    BLOOD, 2003, 102 (11) : 373B - 373B
  • [5] Multiple myeloma cells express CD52 and are sensitive to treatment with CAMPATH-1H.
    Gasparetto, C
    Rooney, BJ
    Houser, L
    Rooney, RJ
    Rizzieri, D
    Long, GD
    Vredenburgh, JJ
    Lassiter, M
    Smith, CA
    Chao, NJ
    BLOOD, 2002, 100 (11) : 812A - 813A
  • [6] Primary plasma cells expressing CD52 are efficiently targeted in vivo by alemtuzumab.
    Carlo-Stella, C
    Di Nicola, M
    Longoni, P
    Cleris, L
    Milanesi, M
    Lavazza, C
    Milani, R
    Carrabba, M
    Formelli, F
    Gianni, AM
    Corradini, P
    BLOOD, 2004, 104 (11) : 943A - 943A
  • [7] Quantification of CD52 antigen expression by normal and leukemic lymphoid cells:: Indications for anti-CD52 antibody therapy?
    Guarini, A
    De Propris, MS
    Intoppa, S
    Milani, ML
    Lisci, A
    Martinelli, M
    Vitale, A
    Mauro, FR
    Foà, R
    BLOOD, 2005, 106 (11) : 60B - 60B
  • [8] Expression of RANKL in myeloma cell lines and bone marrow plasma cells in patients with multiple myeloma.
    Sezer, O
    Heider, U
    Jakob, C
    Eucker, J
    Niemöller, K
    Zavrski, I
    Possinger, K
    BLOOD, 2001, 98 (11) : 304B - 304B
  • [9] Adenovirus mediated gene transfer induces high-level and selective expression of functional CD154 (CD40 ligand) on primary human myeloma cells and cell lines.
    Bashey, A
    Cantwell, MJ
    Wierda, WG
    Kipps, TJ
    BLOOD, 1999, 94 (10) : 179A - 179A
  • [10] Detection and Quantification of Cereblon Protein and mRNA in Multiple Myeloma Cell Lines and Primary CD138+ multiple Myeloma Cells
    Gandhi, Anita K.
    Avet-Loiseau, Herve
    Waldman, Michelle
    Thakurta, Anjan
    Aukerman, Sharon L.
    Chen, Gengxin
    Mendy, Derek
    Rychak, Emily
    Miller, Karen
    Gaidarova, Svetlana
    Gonzales, Michael
    Cathers, Brian
    Schafer, Peter H.
    Daniel, Tom O.
    Lopez-Girona, Antonia
    Chopra, Rajesh
    BLOOD, 2012, 120 (21)
12345